WARF: P160170US01

  • Assigned to WARF as biological material.

Wis.L Master Cell Bank for Vaccine Development


James Gern

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in a master cell bank of human fetal fibroblasts that have been extensively characterized and are FDA-qualified for virus production.
OVERVIEWFDA-qualified cell lines must be used for virus production for human vaccines. There are relatively few of these lines available and several (WI-38, MRC-5) used for virus production are becoming senescent. Due to current and potential restrictions, fetal tissue-derived lines are not being replaced as they senesce.
THE INVENTIONUW–Madison researchers have developed a master cell bank of Wis.L cells (primary human fetal pulmonary fibroblasts) for commercial use as a substrate for the production of viral vaccines. The cells were first isolated by the State Laboratory of Hygiene (SLH) in 1968 and have been used extensively by SLH in viral diagnostic laboratories to isolate viruses from clinical specimens. The cells also have been used to grow rhinoviruses for inoculation studies. They have been subjected to testing as recommended by the FDA for use in vaccine production or experimental inoculation studies, and are free from extraneous contaminants.
  • Viral vaccine production and research tool
  • Available as a biomaterial
  • FDA-qualified
  • Extensively characterized
  • Isolated prior to HIV and prions
STAGE OF DEVELOPMENTThe Wis.L cells were originally cryopreserved in 1968; in 2003 they were thawed to produce a master cell bank. Defined reagents and procedures were used in the production of the cell bank, with the goal of developing a cell line suitable for the production of viruses or vaccines for human use. In 2009 the cells were used to produce a recombinant rhinovirus inoculum, which was granted an FDA IND for a study using human volunteers.
For More Information About the Inventors
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.